{"pmid":32378030,"pmcid":"PMC7202903","title":"COVID-19-Related Stroke.","text":["COVID-19-Related Stroke.","The COVID-19 pandemic is associated with neurological symptoms and complications including stroke. There is hypercoagulability associated with COVID-19 that is likely a \"sepsis-induced coagulopathy\" and may predispose to stroke. The SARS-CoV-2 virus binds to angiotensin-converting enzyme 2 (ACE2) present on brain endothelial and smooth muscle cells. ACE2 is a key part of the renin angiotensin system (RAS) and a counterbalance to angiotensin-converting enzyme 1 (ACE1) and angiotensin II. Angiotensin II is proinflammatory, is vasoconstrictive, and promotes organ damage. Depletion of ACE2 by SARS-CoV-2 may tip the balance in favor of the \"harmful\" ACE1/angiotensin II axis and promote tissue injury including stroke. There is a rationale to continue to treat with tissue plasminogen activator for COVID-19-related stroke and low molecular weight heparinoids may reduce thrombosis and mortality in sepsis-induced coagulopathy.","Transl Stroke Res","Hess, David C","Eldahshan, Wael","Rutkowski, Elizabeth","32378030"],"abstract":["The COVID-19 pandemic is associated with neurological symptoms and complications including stroke. There is hypercoagulability associated with COVID-19 that is likely a \"sepsis-induced coagulopathy\" and may predispose to stroke. The SARS-CoV-2 virus binds to angiotensin-converting enzyme 2 (ACE2) present on brain endothelial and smooth muscle cells. ACE2 is a key part of the renin angiotensin system (RAS) and a counterbalance to angiotensin-converting enzyme 1 (ACE1) and angiotensin II. Angiotensin II is proinflammatory, is vasoconstrictive, and promotes organ damage. Depletion of ACE2 by SARS-CoV-2 may tip the balance in favor of the \"harmful\" ACE1/angiotensin II axis and promote tissue injury including stroke. There is a rationale to continue to treat with tissue plasminogen activator for COVID-19-related stroke and low molecular weight heparinoids may reduce thrombosis and mortality in sepsis-induced coagulopathy."],"journal":"Transl Stroke Res","authors":["Hess, David C","Eldahshan, Wael","Rutkowski, Elizabeth"],"date":"2020-05-08T11:00:00Z","year":2020,"_id":"32378030","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1007/s12975-020-00818-9","keywords":["angiotensin-converting enzyme 2 (ace2)","covid-19","coagulopathy","sars-cov-2","sepsis","stroke"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1666597097428746242,"score":9.490897,"similar":[{"pmid":32492292,"title":"Two hits to the renin-angiotensin system may play a key role in severe COVID-19.","text":["Two hits to the renin-angiotensin system may play a key role in severe COVID-19.","The spike glycoprotein on the virion surface docking onto the angiotensin-converting enzyme (ACE) 2 dimer is an essential step in the process of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in human cells-involves downregulation of ACE2 expression with systemic renin-angiotensin system (RAS) imbalance and promotion of multi-organ damage. In general, the RAS induces vasoconstriction, hypertension, inflammation, fibrosis, and proliferation via the ACE/Ang II/Ang II type 1 receptor (AT1R) axis and induces the opposite effects via the ACE2/Ang (1-7)/Mas axis. The RAS may be activated by chronic inflammation in hypertension, diabetes, obesity, and cancer. SARS-CoV-2 induces the ACE2 internalization and shedding, leading to the inactivation of the ACE2/Ang (1-7)/Mas axis. Therefore, we hypothesize that two hits to the RAS drives COVID-19 progression. In brief, the first hit originates from chronic inflammation activating the ACE/Ang II/AT1R axis, and the second originates from the COVID-19 infection inactivating the ACE2/Ang (1-7)/Mas axis. Moreover, the two hits to the RAS may be the primary reason for increased mortality in patients with COVID-19 who have comorbidities and may serve as a therapeutic target for COVID-19 treatment.","Kaohsiung J Med Sci","Tseng, Yu-Hsin","Yang, Rei-Cheng","Lu, Tzong-Shi","32492292"],"abstract":["The spike glycoprotein on the virion surface docking onto the angiotensin-converting enzyme (ACE) 2 dimer is an essential step in the process of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in human cells-involves downregulation of ACE2 expression with systemic renin-angiotensin system (RAS) imbalance and promotion of multi-organ damage. In general, the RAS induces vasoconstriction, hypertension, inflammation, fibrosis, and proliferation via the ACE/Ang II/Ang II type 1 receptor (AT1R) axis and induces the opposite effects via the ACE2/Ang (1-7)/Mas axis. The RAS may be activated by chronic inflammation in hypertension, diabetes, obesity, and cancer. SARS-CoV-2 induces the ACE2 internalization and shedding, leading to the inactivation of the ACE2/Ang (1-7)/Mas axis. Therefore, we hypothesize that two hits to the RAS drives COVID-19 progression. In brief, the first hit originates from chronic inflammation activating the ACE/Ang II/AT1R axis, and the second originates from the COVID-19 infection inactivating the ACE2/Ang (1-7)/Mas axis. Moreover, the two hits to the RAS may be the primary reason for increased mortality in patients with COVID-19 who have comorbidities and may serve as a therapeutic target for COVID-19 treatment."],"journal":"Kaohsiung J Med Sci","authors":["Tseng, Yu-Hsin","Yang, Rei-Cheng","Lu, Tzong-Shi"],"date":"2020-06-04T11:00:00Z","year":2020,"_id":"32492292","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1002/kjm2.12237","keywords":["coronavirus disease 2019","renin-angiotensin system)","two hits"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1668892169379774464,"score":331.22327},{"pmid":32391169,"pmcid":"PMC7202902","title":"Is the use of RAS inhibitors safe in the current era of COVID-19 pandemic?","text":["Is the use of RAS inhibitors safe in the current era of COVID-19 pandemic?","Antihypertensive drugs are one of the most widely used pharmacologic agent in the world and it is predominantly used in the elderly subjects. Pneumonia is the most common cause of death in the extremely old subject. During infection and its complication such as sepsis, hypotension could be exacerbated by antihypertensive drugs because homeostasis mechanisms such as sodium balance, renin angiotensin aldosterone system and/or sympathetic nervous system can be mitigated by antihypertensive drug therapy. Severe Acute Respiratory Syndrome-Coronavirus-1 and 2 viral surface protein is known to attach angiotensin converting enzyme 2 (ACE2) on the cell membrane to facilitate viral entry into the cytoplasm. Despite the theoretical concerns of increased ACE2 expression by Renin-Angiotensin-Aldosterone system (RAS) blockade, there is no evidence that RAS inhibitors are harmful during COVID-19 infection and have in fact been shown to be beneficial in animal studies. Therefore, it is recommended to maintain RAS blockade during the current corona virus pandemic.","Clin Hypertens","Park, Sungha","Lee, Hae Young","Cho, Eun Joo","Sung, Ki Chul","Kim, Juhan","Kim, Dae-Hee","Ihm, Sang-Hyun","Kim, Kwang-Il","Sohn, Il-Suk","Chung, Wook-Jin","Kim, Hyeon Chang","Ryu, Sung Kee","Pyun, Wook Bum","Shin, Jinho","32391169"],"abstract":["Antihypertensive drugs are one of the most widely used pharmacologic agent in the world and it is predominantly used in the elderly subjects. Pneumonia is the most common cause of death in the extremely old subject. During infection and its complication such as sepsis, hypotension could be exacerbated by antihypertensive drugs because homeostasis mechanisms such as sodium balance, renin angiotensin aldosterone system and/or sympathetic nervous system can be mitigated by antihypertensive drug therapy. Severe Acute Respiratory Syndrome-Coronavirus-1 and 2 viral surface protein is known to attach angiotensin converting enzyme 2 (ACE2) on the cell membrane to facilitate viral entry into the cytoplasm. Despite the theoretical concerns of increased ACE2 expression by Renin-Angiotensin-Aldosterone system (RAS) blockade, there is no evidence that RAS inhibitors are harmful during COVID-19 infection and have in fact been shown to be beneficial in animal studies. Therefore, it is recommended to maintain RAS blockade during the current corona virus pandemic."],"journal":"Clin Hypertens","authors":["Park, Sungha","Lee, Hae Young","Cho, Eun Joo","Sung, Ki Chul","Kim, Juhan","Kim, Dae-Hee","Ihm, Sang-Hyun","Kim, Kwang-Il","Sohn, Il-Suk","Chung, Wook-Jin","Kim, Hyeon Chang","Ryu, Sung Kee","Pyun, Wook Bum","Shin, Jinho"],"date":"2020-05-12T11:00:00Z","year":2020,"_id":"32391169","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1186/s40885-020-00144-0","keywords":["2019 novel coronavirus","ace inhibitor","ace2","angiotensin receptor blocker","antihypertensive drugs","covid-19","hypertension","infection","pandemic","sars","sars-cov-2","sepsis"],"e_drugs":["Sodium","Aldosterone"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1666528580155211776,"score":321.50082},{"pmid":32504925,"title":"What would Sergio Ferreira say to your physician in this war against COVID-19: How about kallikrein/kinin system?","text":["What would Sergio Ferreira say to your physician in this war against COVID-19: How about kallikrein/kinin system?","Coronavirus disease 2019 (COVID-19) is an infectious disease with fast spreading all over the world caused by the SARS-CoV-2 virus which can culminate in a severe acute respiratory syndrome by the injury caused in the lungs. However, other organs can be also damaged. SARS-CoV-2 enter into the host cells using the angiotensin-converting enzyme 2 (ACE2) as receptor, like its ancestor SARS-CoV. ACE2 is then downregulated in lung tissues with augmented serum levels of ACE2 in SARS-CoV-2 patients. Interestingly, ACE2(+) organs reveal the symptomatic repercussions, which are signals of the infection such as dry cough, shortness of breath, heart failure, liver and kidney damage, anosmia or hyposmia, and diarrhea. ACE2 exerts a chief role in the renin-angiotensin system (RAS) by converting angiotensin II to angiotensin-(1-7) that activates Mas receptor, inhibits ACE1, and modulates bradykinin (BK) receptor sensitivity, especially the BK type 2 receptor (BKB2R). ACE2 also hydrolizes des-Arg(9)-bradykinin (DABK), an active BK metabolite, agonist at BK type 1 receptors (BKB1R), which is upregulated by inflammation. In this opinion article, we conjecture a dialogue by the figure of Sergio Ferreira which brought together basic science of classical pharmacology and clinical repercussions in COVID-19, then we propose that in the course of SARS-CoV-2 infection: i) downregulation of ACE2 impairs the angiotensin II and DABK inactivation; ii) BK and its metabolite DABK seems to be in elevated levels in tissues by interferences in kallikrein/kinin system; iii) BK1 receptor contributes to the outbreak and maintenance of the inflammatory response; iv) kallikrein/kinin system crosstalks to RAS and coagulation system, linking inflammation to thrombosis and organ injury. We hypothesize that targeting the kallikrein/kinin system and BKB1R pathway may be beneficial in SARS-CoV-2 infection, especially on early stages. This route of inference should be experimentally verified by SARS-CoV-2 infected mice.","Med Hypotheses","Nicolau, Lucas A D","Magalhaes, Pedro J C","Vale, Mariana L","32504925"],"abstract":["Coronavirus disease 2019 (COVID-19) is an infectious disease with fast spreading all over the world caused by the SARS-CoV-2 virus which can culminate in a severe acute respiratory syndrome by the injury caused in the lungs. However, other organs can be also damaged. SARS-CoV-2 enter into the host cells using the angiotensin-converting enzyme 2 (ACE2) as receptor, like its ancestor SARS-CoV. ACE2 is then downregulated in lung tissues with augmented serum levels of ACE2 in SARS-CoV-2 patients. Interestingly, ACE2(+) organs reveal the symptomatic repercussions, which are signals of the infection such as dry cough, shortness of breath, heart failure, liver and kidney damage, anosmia or hyposmia, and diarrhea. ACE2 exerts a chief role in the renin-angiotensin system (RAS) by converting angiotensin II to angiotensin-(1-7) that activates Mas receptor, inhibits ACE1, and modulates bradykinin (BK) receptor sensitivity, especially the BK type 2 receptor (BKB2R). ACE2 also hydrolizes des-Arg(9)-bradykinin (DABK), an active BK metabolite, agonist at BK type 1 receptors (BKB1R), which is upregulated by inflammation. In this opinion article, we conjecture a dialogue by the figure of Sergio Ferreira which brought together basic science of classical pharmacology and clinical repercussions in COVID-19, then we propose that in the course of SARS-CoV-2 infection: i) downregulation of ACE2 impairs the angiotensin II and DABK inactivation; ii) BK and its metabolite DABK seems to be in elevated levels in tissues by interferences in kallikrein/kinin system; iii) BK1 receptor contributes to the outbreak and maintenance of the inflammatory response; iv) kallikrein/kinin system crosstalks to RAS and coagulation system, linking inflammation to thrombosis and organ injury. We hypothesize that targeting the kallikrein/kinin system and BKB1R pathway may be beneficial in SARS-CoV-2 infection, especially on early stages. This route of inference should be experimentally verified by SARS-CoV-2 infected mice."],"journal":"Med Hypotheses","authors":["Nicolau, Lucas A D","Magalhaes, Pedro J C","Vale, Mariana L"],"date":"2020-06-07T11:00:00Z","year":2020,"_id":"32504925","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1016/j.mehy.2020.109886","keywords":["covid-19","inflammation","kallikrein","kinin"],"locations":["Sergio Ferreira"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1668892488218181632,"score":313.70276},{"pmid":32504450,"title":"Dysfunctional Coagulation in COVID-19: From Cell to Bedside.","text":["Dysfunctional Coagulation in COVID-19: From Cell to Bedside.","Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes coronavirus disease 2019 (COVID-19), which can induce multisystem disease. Human angiotensin-converting enzyme 2 (ACE2) widely expressing in arterial and venous endothelial cells and arterial smooth muscle cells has been identified as a functional receptor for SARS-CoV-2. Dysfunction of ACE2 leads to abnormal activation of the renin-angiotensin system and a systemic endotheliitis that may relate to abnormal coagulation and sepsis. Meanwhile, innate immune response and inflammation activation participate in dysfunctional coagulation. Previous research indicated that dysfunctional coagulation was one of the important risk factors accountable for a high risk of severe disease and death in patients with COVID-19. Understanding the possible mechanisms of dysfunctional coagulation and appropriate anticoagulation therapeutic strategies are important to prevent disease deterioration and reduce fatality rates during the ongoing COVID-19 pandemic.","Adv Ther","Wang, Jie","Saguner, Ardan M","An, Jiaqi","Ning, Yuye","Yan, Yang","Li, Guoliang","32504450"],"abstract":["Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes coronavirus disease 2019 (COVID-19), which can induce multisystem disease. Human angiotensin-converting enzyme 2 (ACE2) widely expressing in arterial and venous endothelial cells and arterial smooth muscle cells has been identified as a functional receptor for SARS-CoV-2. Dysfunction of ACE2 leads to abnormal activation of the renin-angiotensin system and a systemic endotheliitis that may relate to abnormal coagulation and sepsis. Meanwhile, innate immune response and inflammation activation participate in dysfunctional coagulation. Previous research indicated that dysfunctional coagulation was one of the important risk factors accountable for a high risk of severe disease and death in patients with COVID-19. Understanding the possible mechanisms of dysfunctional coagulation and appropriate anticoagulation therapeutic strategies are important to prevent disease deterioration and reduce fatality rates during the ongoing COVID-19 pandemic."],"journal":"Adv Ther","authors":["Wang, Jie","Saguner, Ardan M","An, Jiaqi","Ning, Yuye","Yan, Yang","Li, Guoliang"],"date":"2020-06-07T11:00:00Z","year":2020,"_id":"32504450","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1007/s12325-020-01399-7","keywords":["ace2","covid-19","dysfunctional coagulation","sars-cov-2"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1668892488215035904,"score":311.6769},{"pmid":32333398,"title":"A hypothesis for pathobiology and treatment of COVID-19: the centrality of ACE1/ACE2 imbalance.","text":["A hypothesis for pathobiology and treatment of COVID-19: the centrality of ACE1/ACE2 imbalance.","Angiotensin converting enzyme-2 (ACE2) is the receptor for the coronavirus SARS-CoV-2, which causes COVID-19. We propose the following hypothesis: Imbalance in the action of ACE1- and ACE2-derived peptides, thereby enhancing Angiotensin-II (ANG II) signaling, a primary driver of COVID-19 pathobiology. ACE1/ACE2 imbalance occurs due to the binding of SARS-CoV-2 to ACE2, reducing ACE2-mediated conversion of ANG II to ANG peptides that counteract pathophysiological effects of ACE1-generated ANGII. This hypothesis suggests several approaches to treat COVID-19 by restoring ACE1/ACE2 balance: 1) ANG II receptor blockers (ARBs); 2) ACE1 inhibitors (ACEIs); 3) Agonists of receptors activated by ACE2-derived peptides [e.g., ANG (1-7), which activates MAS1]; 4) Recombinant human ACE2 or ACE2 peptides as decoys for the virus. Reducing ACE1/ACE2 imbalance is predicted to blunt COVID-19-associated morbidity and mortality, especially in vulnerable patients. Importantly, approved ARBs and ACEIs can be rapidly repurposed to test their efficacy in treating COVID-19.","Br J Pharmacol","Sriram, Krishna","Insel, Paul A","32333398"],"abstract":["Angiotensin converting enzyme-2 (ACE2) is the receptor for the coronavirus SARS-CoV-2, which causes COVID-19. We propose the following hypothesis: Imbalance in the action of ACE1- and ACE2-derived peptides, thereby enhancing Angiotensin-II (ANG II) signaling, a primary driver of COVID-19 pathobiology. ACE1/ACE2 imbalance occurs due to the binding of SARS-CoV-2 to ACE2, reducing ACE2-mediated conversion of ANG II to ANG peptides that counteract pathophysiological effects of ACE1-generated ANGII. This hypothesis suggests several approaches to treat COVID-19 by restoring ACE1/ACE2 balance: 1) ANG II receptor blockers (ARBs); 2) ACE1 inhibitors (ACEIs); 3) Agonists of receptors activated by ACE2-derived peptides [e.g., ANG (1-7), which activates MAS1]; 4) Recombinant human ACE2 or ACE2 peptides as decoys for the virus. Reducing ACE1/ACE2 imbalance is predicted to blunt COVID-19-associated morbidity and mortality, especially in vulnerable patients. Importantly, approved ARBs and ACEIs can be rapidly repurposed to test their efficacy in treating COVID-19."],"journal":"Br J Pharmacol","authors":["Sriram, Krishna","Insel, Paul A"],"date":"2020-04-26T11:00:00Z","year":2020,"_id":"32333398","source":"PubMed","week":"202017|Apr 20 - Apr 26","doi":"10.1111/bph.15082","keywords":["ace inhibitor","ace2","angiotensin","angiotensin receptor blocker","covid-19","sars-cov-2"],"e_drugs":["Peptides"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1666138493953245184,"score":303.08237}]}